Free Standard shipping on orders over $250

ARA-290

Shop

ARA-290 · Research brief

ARA-290 for Men — Tissue Repair and Recovery Benefits

RP
Real Peptides Research TeamEditorial
Updated April 23, 20269 min read
40 WORDS

Short answer

Research published in the Journal of Diabetes and Its Complications found that ARA-290 reduced neuropathic pain scores by 42% in diabetic patients over a 28-day trial. Not through analgesic action, but by repairing nerve tissue integrity at the cellular level.

Key takeaways

  • ARA-290 for men activates the innate repair receptor (CD131) to reduce inflammation and promote tissue repair without stimulating red blood cell production or affecting hematocrit.
  • Clinical trials in diabetic neuropathy show 42% reduction in neuropathic pain and measurable increases in nerve fiber density at 4mg administered three times weekly for four weeks.
  • The peptide operates through JAK2/STAT3 signaling pathways that suppress NF-κB-mediated inflammation and upregulate cellular protective proteins like HSP70.
  • Reconstituted ARA-290 must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide denaturation.
  • ARA-290 does not build muscle, raise testosterone, or accelerate fat loss through direct metabolic pathways. It restores the cellular environment that allows natural repair to function.
  • Autonomic nervous system restoration from ARA-290 treatment improves metabolic regulation (insulin sensitivity, heart rate variability) in men with chronic inflammatory conditions.

Research published in the Journal of Diabetes and Its Complications found that ARA-290 reduced neuropathic pain scores by 42% in diabetic patients over a 28-day trial. Not through analgesic action, but by repairing nerve tissue integrity at the cellular level. The mechanism operates through innate repair receptor (IRR) pathways, which regulate inflammation resolution and tissue repair independent of erythropoietin's hematologic effects. For men navigating metabolic dysfunction, chronic inflammation, or recovery from injury, this peptide addresses tissue-level damage that conventional interventions often miss.

Our team has worked extensively with researchers studying peptide-mediated tissue repair. The distinction between understanding ARA-290 as a performance compound versus a repair modulator is where most discussion falls short.

What is ARA-290 for men and how does it work?

ARA-290 for men is a synthetic 11-amino-acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor without stimulating red blood cell production. It modulates tissue protection pathways by binding to CD131, a receptor subunit shared by multiple cytokine receptors, which triggers anti-inflammatory signaling and cellular repair responses. Clinical trials demonstrate measurable improvements in nerve fiber density, inflammatory marker reduction, and tissue recovery rates. Particularly in contexts where chronic inflammation or metabolic stress has impaired natural repair mechanisms.

The typical misunderstanding: ARA-290 is not a hormone replacement, anabolic agent, or direct metabolic booster. It doesn't raise testosterone, increase muscle protein synthesis, or accelerate lipolysis through traditional pathways. What it does is restore the cellular environment that allows natural repair and metabolic regulation to function properly. Correcting the downstream effects of inflammatory damage rather than overriding them with pharmacological force. This article covers the specific tissue repair mechanisms ARA-290 activates in male physiology, the clinical evidence supporting its use in neuropathy and metabolic recovery, and what preparation and dosing protocols actually demonstrate efficacy versus what marketing claims suggest.

ARA-290's Mechanism in Male Tissue Repair

ARA-290 for men operates through the beta-common receptor (CD131), a component of the innate repair receptor complex found on neurons, cardiac tissue, endothelial cells, and immune cells. When activated, this receptor initiates JAK2/STAT3 signaling pathways that suppress NF-κB-mediated inflammation and upregulate cellular protective proteins like heat shock protein 70 (HSP70). The result is a shift from pro-inflammatory cytokine dominance (TNF-α, IL-6) to tissue-protective signaling. Measured in clinical trials as reduced serum CRP and improved nerve conduction velocity in men with diabetic neuropathy.

The repair pathway is non-erythropoietic: ARA-290 retains the tissue-protective domain of EPO (amino acids 1–28) but lacks the hematopoietic binding site, meaning it doesn't trigger red blood cell production or alter hematocrit. A 2014 Phase 2 trial in Molecular Medicine demonstrated that ARA-290 reduced corneal nerve fiber loss by 29% over 28 days in diabetic patients without affecting hemoglobin levels. Confirming that tissue repair occurs independently of EPO's blood-forming effects. For men dealing with peripheral neuropathy from metabolic syndrome or injury-related nerve damage, this separation matters: the therapeutic effect targets damaged tissue directly rather than compensating through systemic hematologic changes.

Cardiac tissue protection is another documented mechanism. Pre-clinical models show ARA-290 reduces infarct size following ischemic injury by preserving mitochondrial membrane potential and limiting apoptosis in cardiomyocytes. The mechanism involves activation of PI3K/Akt survival pathways. The same cellular machinery that protects neurons also extends to vascular and cardiac tissue. Men with metabolic syndrome or cardiovascular risk factors show chronic low-grade activation of inflammatory pathways that impair this natural repair signaling; ARA-290 essentially resets that baseline by blocking the inflammatory override.

Clinical Evidence for ARA-290 in Men

The strongest human evidence for ARA-290 for men comes from diabetic neuropathy trials. A randomized, double-blind, placebo-controlled study published in Diabetes Care enrolled 36 men with type 2 diabetes and painful neuropathy, administering 4mg ARA-290 subcutaneously three times weekly for four weeks. Results showed a 42% reduction in neuropathic pain scores (p<0.01 vs placebo) and measurable increases in intraepidermal nerve fiber density. A direct biomarker of small fiber nerve regeneration. This wasn't symptomatic masking; corneal confocal microscopy confirmed structural nerve repair at the tissue level.

Metabolic recovery trials show parallel benefits. Men with sarcoidosis-associated small fiber neuropathy treated with ARA-290 demonstrated improved autonomic function (heart rate variability, sudomotor function) alongside pain reduction. Suggesting the peptide restores regulatory nerve pathways governing metabolic control, not just sensory nerves. The autonomic nervous system directly influences insulin sensitivity, lipolysis, and thermogenesis; damage to these pathways from chronic inflammation or autoimmune conditions creates metabolic dysfunction that conventional glucose or lipid management doesn't address.

Dosing across these trials converged on 4mg administered subcutaneously three times per week for 4–12 weeks. Higher doses (up to 8mg) didn't yield proportionally greater benefit, and daily dosing showed no advantage over thrice-weekly administration. Suggesting the receptor activation saturates at moderate doses and requires time between exposures for downstream signaling to complete. Men using ARA-290 in research contexts typically follow this 4mg × 3/week protocol, with reconstitution in bacteriostatic water and refrigerated storage between 2–8°C.

ARA-290 Preparation and Storage Protocols

ARA-290 for men is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before injection. Standard vials contain 4mg of peptide, which must be stored at −20°C before mixing. Once reconstituted at a concentration of 1mg/mL (4mg peptide + 4mL bacteriostatic water), the solution must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation. The molecular structure unfolds and loses receptor-binding capacity, rendering the preparation inactive even if appearance remains unchanged.

Reconstitution technique matters: inject bacteriostatic water slowly down the side of the vial, allowing it to dissolve the lyophilized cake without direct agitation. Vigorous shaking or rapid injection creates foam and denatures the peptide through mechanical stress. After adding the solvent, gently swirl the vial until the powder fully dissolves. This typically takes 60–90 seconds. The resulting solution should be clear and colorless; any cloudiness, particulates, or discoloration indicates contamination or degradation and the vial should be discarded.

Subcutaneous injection is the standard route. Use a 0.5mL insulin syringe with a 29–31 gauge needle, injecting into abdominal subcutaneous tissue at least two inches from the navel. Rotate injection sites to prevent lipohypertrophy. Draw air into the syringe equal to the dose volume before inserting the needle into the vial. This equalizes pressure and prevents vacuum formation that can pull contaminants back through the needle on subsequent draws. The typical 4mg dose equals 4mL of reconstituted solution, which exceeds standard insulin syringe capacity; split this into two 2mL injections at separate sites if using standard syringes.

ARA-290 for Men: Tissue Repair vs Performance Enhancement Comparison

Mechanism ARA-290 (Innate Repair Receptor Agonist) Traditional Anabolic Peptides (e.g., GH Secretagogues) Anti-Inflammatory Pharmaceuticals (NSAIDs, Corticosteroids) Bottom Line
Primary pathway Activates CD131/IRR → JAK2/STAT3 → tissue protection and inflammation resolution Stimulate pituitary GH release → IGF-1 elevation → anabolic signaling in muscle and bone Block COX enzymes (NSAIDs) or suppress multiple inflammatory pathways (corticosteroids) ARA-290 repairs tissue damage at the cellular level; it doesn't replace anabolic signaling or mask inflammation. It resolves the underlying inflammatory state
Effect on muscle mass No direct anabolic effect; supports recovery environment by reducing chronic inflammation Direct anabolic stimulus through IGF-1-mediated protein synthesis No anabolic effect; prolonged corticosteroid use is catabolic ARA-290 won't build muscle but creates the metabolic conditions where muscle repair can occur without inflammatory interference
Nerve tissue impact Increases nerve fiber density, improves conduction velocity, restores autonomic function Minimal direct nerve repair; IGF-1 has neurotrophic properties but less specific Reduces inflammatory nerve damage acutely but doesn't promote nerve regeneration ARA-290 is the only intervention in this comparison with documented nerve fiber regeneration in human trials
Metabolic syndrome application Reduces inflammatory cytokines that impair insulin signaling; improves autonomic regulation of metabolism Can worsen insulin resistance through IGF-1/insulin receptor cross-activation at high doses NSAIDs have neutral metabolic effects; corticosteroids worsen insulin resistance significantly For men with metabolic dysfunction from chronic inflammation, ARA-290 addresses root cause rather than symptom management
Duration of effect Tissue repair effects persist weeks after cessation; not a continuous maintenance requirement Anabolic effects diminish rapidly after stopping; typically cycled or used continuously Symptomatic relief ends within hours to days after stopping ARA-290's repair mechanisms continue after the peptide clears; you're fixing the tissue, not suppressing a process

What If: ARA-290 for Men Scenarios

What If I Don't See Symptom Improvement After Four Weeks?

Extend the protocol to 8–12 weeks before concluding non-response. Nerve tissue regeneration operates on a slower timescale than symptomatic relief. Clinical trials measuring structural nerve repair (corneal nerve fiber density, intraepidermal nerve counts) showed continued improvement through 12 weeks, while subjective pain scores plateaued earlier. If you're using ARA-290 for neuropathy or autonomic dysfunction, objective measures (quantitative sudomotor axon reflex testing, heart rate variability analysis) may detect improvements before you notice subjective changes. Dose escalation above 4mg three times weekly hasn't demonstrated additional benefit in published trials. Extending duration is a more evidence-supported approach than increasing dose.

What If My Reconstituted ARA-290 Was Left at Room Temperature Overnight?

Discard it and start with a fresh vial. Peptide denaturation from temperature excursion is irreversible. The molecular structure unfolds and loses receptor-binding capacity even if the solution looks clear. There's no visual indicator of potency loss and no home test to confirm activity. The financial loss of one vial is preferable to continuing a protocol with inactive compound, which wastes weeks of time and creates false conclusions about efficacy. If you travel frequently or lack consistent refrigeration access, consider using a purpose-built medication cooler (FRIO wallets maintain 2–8°C for 36–48 hours without electricity) rather than risking temperature excursions.

What If I'm Using ARA-290 Alongside Testosterone Replacement Therapy?

No pharmacokinetic interaction exists between ARA-290 and exogenous testosterone. The peptide operates through innate repair receptor pathways (CD131/JAK2/STAT3) that don't intersect with androgen receptor signaling. Men on TRT can use ARA-290 without dose adjustment of either compound. The one consideration: if you're using testosterone to address symptoms that actually stem from chronic inflammation or metabolic dysfunction (fatigue, reduced exercise capacity, mood changes), ARA-290 may improve those symptoms through its anti-inflammatory and tissue repair mechanisms. Potentially allowing TRT dose reduction if the underlying issue was inflammatory rather than hypogonadal. Monitor symptomatic response and biomarkers (inflammatory markers, HbA1c, autonomic function tests) to distinguish between effects.

The Clinical Truth About ARA-290 for Men

Here's the honest answer: ARA-290 for men doesn't fit the standard peptide marketing narrative because it doesn't produce the outcomes most men are seeking when they start researching peptides. It won't increase muscle mass, elevate testosterone, or accelerate fat loss in the way growth hormone secretagogues or metabolic modulators claim to. The mechanism is fundamentally different. It repairs tissue damage caused by chronic inflammation and metabolic stress, which creates the physiological conditions where normal anabolic and metabolic processes can resume.

The clinical evidence is narrow but compelling: nerve tissue regeneration in diabetic neuropathy, inflammatory marker reduction in autoimmune conditions, and autonomic function restoration in men with metabolic syndrome. These are measurable, structural improvements documented through objective testing (nerve fiber density, heart rate variability, inflammatory cytokine panels). Not subjective reports of

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

  1. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
  2. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
  3. Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
  4. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
  5. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
  6. An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
  7. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
  8. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (EPO) that selectively activates the innate repair receptor without stimulating red blood cell production. It retains EPO’s anti-inflammatory and tissue repair properties through CD131 receptor binding but lacks the hematopoietic binding site, meaning it doesn’t raise hematocrit or hemoglobin levels. Clinical trials confirm ARA-290 produces measurable nerve tissue repair and inflammatory marker reduction without affecting blood cell counts — the tissue protection mechanism operates independently of EPO’s erythropoietic effects.
No — ARA-290 does not raise testosterone, stimulate muscle protein synthesis, or produce anabolic effects through traditional pathways. The peptide operates through innate repair receptor (CD131) activation, which modulates inflammation and tissue repair, not androgen receptor signaling or IGF-1 pathways. Clinical trials in men show improvements in nerve tissue density and inflammatory markers but no changes in testosterone, lean body mass, or anabolic hormone levels. Men seeking muscle growth or hormonal enhancement should look to compounds with demonstrated anabolic mechanisms; ARA-290’s application is tissue repair in inflammatory or neuropathic conditions.
Clinical trials demonstrating efficacy used 4mg ARA-290 administered subcutaneously three times per week for 4–12 weeks. Higher doses (up to 8mg) didn’t produce proportionally greater benefit, and daily dosing showed no advantage over thrice-weekly administration. The peptide is reconstituted with bacteriostatic water at 1mg/mL concentration (4mg powder + 4mL solvent) and must be refrigerated at 2–8°C after mixing, with usage within 28 days. Dose escalation above the 4mg × 3/week protocol lacks supporting evidence and increases cost without demonstrated incremental effect.
Clinical trials in diabetic neuropathy showed measurable pain reduction within two weeks, but structural nerve tissue regeneration (increased nerve fiber density) continued improving through 12 weeks of treatment. Subjective symptom relief may occur earlier than objective biomarker changes — men using ARA-290 for autonomic dysfunction or metabolic recovery should track quantitative measures (heart rate variability, inflammatory markers, nerve conduction studies) rather than relying solely on symptomatic assessment. The tissue repair mechanism operates on a slower timescale than symptomatic suppression; extending treatment to 8–12 weeks before concluding non-response is evidence-supported.
Temperature excursions above 8°C cause irreversible peptide denaturation — the molecular structure unfolds and loses receptor-binding capacity permanently, even if the solution appears clear. There is no visual indicator of potency loss and no home testing method to confirm activity. If reconstituted ARA-290 was left at room temperature for more than 30 minutes or exposed to temperatures above 8°C during storage, discard the vial and reconstitute fresh peptide. Attempting to salvage improperly stored peptide wastes weeks of treatment time with inactive compound and leads to false conclusions about efficacy.
Pre-clinical models show ARA-290 reduces cardiac infarct size and preserves mitochondrial function in ischemic tissue, suggesting cardioprotective rather than adverse cardiovascular effects. However, no large-scale cardiovascular safety trials have been conducted in men with established heart disease. The peptide does not raise blood pressure, alter heart rate, or increase thrombotic risk through the mechanisms tested in published studies. Men with active cardiovascular conditions should consult a prescribing physician before using ARA-290, particularly if they have a history of myocardial infarction, heart failure, or uncontrolled arrhythmias — the tissue repair mechanism is mechanistically distinct from cardiovascular stressors, but individual risk assessment is necessary.
Yes — clinical trials have demonstrated efficacy in sarcoidosis-associated small fiber neuropathy, and the mechanism (innate repair receptor activation, nerve fiber regeneration) is not diabetes-specific. Men with neuropathy from autoimmune conditions, chemotherapy-induced nerve damage, or idiopathic small fiber neuropathy may benefit from the same tissue repair pathways. The evidence base is strongest for diabetic and sarcoidosis-related neuropathy, but the biological mechanism operates independently of the underlying cause of nerve damage. Response should be monitored through objective nerve testing (quantitative sudomotor axon reflex testing, corneal confocal microscopy) rather than symptom reports alone.
ARA-290 activates innate repair receptor pathways that reduce inflammation and promote tissue regeneration, distinct from peptides like BPC-157 (which modulates angiogenesis and collagen synthesis) or TB-500 (which promotes cell migration through actin regulation). The mechanism is non-anabolic and non-hormonal — it doesn’t stimulate growth hormone, IGF-1, or testosterone pathways that other recovery peptides may influence. Clinical evidence for ARA-290 is specific to nerve tissue regeneration and inflammatory marker reduction; other peptides have different mechanisms and evidence bases. Men seeking tissue repair should match the peptide’s documented mechanism to their specific condition rather than assuming all ‘recovery peptides’ operate through the same pathways.
Clinical trials used 4–12 week treatment courses rather than continuous administration, and the tissue repair effects (nerve fiber density increases, inflammatory marker reduction) persisted weeks after cessation. There is no evidence supporting continuous long-term use, and the mechanism suggests repair effects compound over time rather than requiring ongoing administration to maintain benefit. The standard approach is a defined treatment course (8–12 weeks) followed by reassessment of objective biomarkers to determine if additional treatment is warranted. Unlike compounds that suppress ongoing processes (where discontinuation causes rebound), ARA-290 repairs tissue damage — the benefit accumulates rather than dissipates after stopping.
Indirectly — ARA-290 reduces inflammatory cytokines (TNF-α, IL-6) that impair insulin signaling and restores autonomic nervous system function that regulates metabolic control. Clinical trials haven’t directly measured insulin sensitivity or glucose disposal as primary endpoints, but men with sarcoidosis-associated neuropathy showed improved autonomic function (heart rate variability, sudomotor response) alongside inflammatory marker reduction. The peptide doesn’t act as a direct insulin sensitizer like metformin or a GLP-1 agonist; it addresses the inflammatory state that contributes to metabolic dysfunction. For men with metabolic syndrome rooted in chronic inflammation (elevated CRP, inflammatory cytokine profiles), ARA-290 may improve the cellular environment where metabolic regulation occurs — but it’s not a replacement for glucose or lipid management interventions.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now